Niagen Bioscience, Inc.

Niagen Bioscience, Inc. develops and commercializes Niagen-branded nicotinamide riboside products across consumer supplements, ingredient supply, and pharmaceutical applications. The company operates through consumer products, ingredients, and pharmaceutical-oriented research activities, with sales in the United States and select international markets.

13,1 %

64,3 %

13,4 %

+29,9 %

4.86

3.83

— Niagen Bioscience, Inc.
%
Consumer Products75% Finished dietary supplement products sold under the Tru Niagen® brand and related practitioner-facing test kits.
Ingredients22% Food-grade and pharmaceutical-grade Niagen® ingredients sold to manufacturers, outsourcing facilities, and compounding pharmacies.
Analytical Reference Standards and Services3% Natural product fine chemicals and related research services historically sold to technical and research customers.
Pharmaceutical Segment0% Research and development of a therapeutic candidate for rare advanced aging diseases, without commercial sales.

The company sells to consumers seeking NAD+ and healthy-aging supplements, primarily through Tru Niagen® and related...

  • Direct-to-consumer supplement buyersprimary

    Consumers purchase Tru Niagen® through the company’s e-commerce channels for daily supplementation and healthy-aging use.

  • Distribution and retail partnersprimary

    Authorized resellers, marketplaces, and specialty retail partners buy finished products for broader consumer reach.

  • Ingredient manufacturersprimary

    Consumer-product manufacturers buy food-grade Niagen® as an input for dietary supplement and food formulations.

  • 503B outsourcing facilities and compounding pharmaciessecondary

    These customers buy pharmaceutical-grade Niagen® for compounding under applicable regulatory requirements.

  • Healthcare practitionerssecondary

    Practitioners buy NAD+ test kits and may also support patient access to Niagen Plus-related offerings.

  • Research and technical customersemerging

    Scientific and laboratory customers buy analytical reference standards and related research services.

The company is headquartered in the United States and generates most of its business there, especially through direct...

  • •United States is the core market for consumer and ingredient sales
  • •Canada is served through direct-to-consumer e-commerce
  • •Select Asia-Pacific markets support international consumer distribution
  • •Europe and the Middle East are served through regional partners
  • •International sales depend on local regulatory feasibility and partner networks

The company’s strategy centers on expanding Tru Niagen® consumer demand while deepening ingredient adoption with...

01
Scale consumer brand demandshort-term

Tru Niagen® is the main commercial engine and supports repeat purchases and brand equity.

02
Broaden ingredient commercializationmedium-term

Ingredient sales diversify the business and leverage the same core Niagen technology across multiple end markets.

03
Expand international reachmedium-term

International partners increase addressable market size without building a full direct sales force in every country.

04
Advance pharmaceutical developmentlong-term

A successful therapeutic program could create a higher-value, patent-protected revenue stream.

The business depends heavily on consumer acceptance of Tru Niagen® and on maintaining effective marketing,...

high

Dependence on Tru Niagen® consumer sales

A large share of revenue is tied to one branded product family, so demand softness would affect the whole business.

Scope
Consumer Products
Materiality
high
high

Regulatory and compliance risk

Dietary supplements, ingredient claims, and compounding activities are subject to FDA, FTC, and local rules.

Scope
US and international supplement/compounding channels
Materiality
high
high

Pharmaceutical development uncertainty

Drug development requires successful R&D, regulatory approval, and patent protection before commercialization.

Scope
Pharmaceutical segment
Materiality
high
medium

Third-party clinic and partner reputation risk

The brand can be affected by conduct at clinics or by resellers even when the company does not control operations.

Scope
Niagen Plus and partner channels
Materiality
medium
medium

Competitive pressure

Larger wellness and ingredient companies may outspend the company on marketing, distribution, and product development.

Scope
Consumer supplements and ingredients
Materiality
high
Revenue recognition under ASC 606
Affects net sales timing and comparability across quarters
Deferred revenue and reserves
Can change reported revenue and liabilities
Intangible assets and patent-related amortization
Affects operating expense and asset carrying values
Stock-based compensation
Affects operating expense, equity, and cash flow presentation

NEOGEN CORP

NEOG · In Vitro & In Vivo Diagnostic Substances

NIKA PHARMACEUTICALS, INC

NIKA · Pharmaceutical Preparations

Neurogene Inc.

NGNE · Pharmaceutical Preparations

NATURAL ALTERNATIVES INTERNATIONAL INC

NAII · Medicinal Chemicals & Botanical Products

ProtoKinetix, Inc.

PKTX · Pharmaceutical Preparations

BioAge Labs, Inc.

BIOA · Pharmaceutical Preparations

: 29/04/2026